Singapore Diabetes Device Market Sample Report 2022 to 2030
salonishah296132
78 views
65 slides
Sep 02, 2024
Slide 1 of 65
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
About This Presentation
Singapore Diabetes Devices Market is expected to grow from $27 Mn in 2022 to $50 Mn in 2030 with a CAGR of 7.80% for the forecasted year 2022-30. An increase in the number of cases of diabetes, a shift in urbanization, and an increase in sedentary lifestyles are the main factors propelling the Singa...
Slide Content
Singapore Diabetes
Device Market Analysis
Sample Report
June 2024
Device Market Analysis
Sample Report
June 2024
This report presents a strategic analysis of the Singapore Diabetes
Device Market and a forecast for its development in the medium and
long term. It provides a comprehensive overview of the market value,
dynamics, segmentation, main players, growth and demand drivers,
challenges & future outlook, etc. This is one of the most comprehensive
reports about the Singapore Diabetes Device Market, and offers
unmatched value, accuracy, and expert insights.
Device Market and a forecast for its development in the medium and
long term. It provides a comprehensive overview of the market value,
dynamics, segmentation, main players, growth and demand drivers,
challenges & future outlook, etc. This is one of the most comprehensive
reports about the Singapore Diabetes Device Market, and offers
unmatched value, accuracy, and expert insights.
3 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2023
Forecast Period 2024-2030
Report Coverage
Market Overview, Size & Forecasting, Market Segmentation, Growth Factors and Trends, Competitive
Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement
Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Currency Conversion 1 SGD = 0.74 USD
Research Approach Secondary Research (90%), Primary Research (10%)
Report Scope
Report Attribute Details
Number of Pages 70-80
Base Year for Estimation 2023
Forecast Period 2024-2030
Report Coverage
Market Overview, Size & Forecasting, Market Segmentation, Growth Factors and Trends, Competitive
Landscape, Key Company Profiles, Government Policies, Regulatory Landscape, Reimbursement
Scenario
Quantitative Units Revenue in USD Million/Billion (Mn/Bn)
Currency Conversion 1 SGD = 0.74 USD
Research Approach Secondary Research (90%), Primary Research (10%)
Report Scope
4 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
CONTENT PG. NO.
1. Market Overview 07-15
1.1 Singapore Diabetes Device Market Overview
1.2 Diabetes Device Market Overview: Global
1.3 Demographic Overview: Singapore
1.4 Economic Overview: Singapore
1.5 Diabetes Device Market Overview: Singapore
1.6 Healthcare Overview: Singapore
1.7 Budget of Singapore Government for Public Insurance
2. Epidemiology 16-18
2.1 Prevalence
2.2 Diabetes Management Devices
3. Market Size and Forecasting 19-24
3.1 Singapore Diabetes Device Market Size and Forecasts
Table of Content
CONTENT PG. NO.
1. Market Overview 07-15
1.1 Singapore Diabetes Device Market Overview
1.2 Diabetes Device Market Overview: Global
1.3 Demographic Overview: Singapore
1.4 Economic Overview: Singapore
1.5 Diabetes Device Market Overview: Singapore
1.6 Healthcare Overview: Singapore
1.7 Budget of Singapore Government for Public Insurance
2. Epidemiology 16-18
2.1 Prevalence
2.2 Diabetes Management Devices
3. Market Size and Forecasting 19-24
3.1 Singapore Diabetes Device Market Size and Forecasts
Table of Content
5 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
CONTENT PG. NO.
3.2 Snapshot of Singapore Diabetes Device Market Segmentation
3.2.1 Market Segmentation: By Device Type
3.2.2 Market Segmentation: By Distribution
3.2.3 Market Segmentation: By End User
4. Market Dynamics 25-30
4. Snapshot Of Market Growth Drivers And Restraints
4.1 Market Growth Drivers
4.2 Market Growth Restraints
5. Competitive Landscape 31-38
5.1 Key Players in Singapore Diabetes Device Market
5.1.1 Medtronic (Continued)
5.1.2 Dexcom
5.1.3 Abbott Laboratories
Table of Content
CONTENT PG. NO.
3.2 Snapshot of Singapore Diabetes Device Market Segmentation
3.2.1 Market Segmentation: By Device Type
3.2.2 Market Segmentation: By Distribution
3.2.3 Market Segmentation: By End User
4. Market Dynamics 25-30
4. Snapshot Of Market Growth Drivers And Restraints
4.1 Market Growth Drivers
4.2 Market Growth Restraints
5. Competitive Landscape 31-38
5.1 Key Players in Singapore Diabetes Device Market
5.1.1 Medtronic (Continued)
5.1.2 Dexcom
5.1.3 Abbott Laboratories
Table of Content
6 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
CONTENT PG. NO.
5.1.4 Roche
5.1.5 Johnson & Johnson
5.1.6 Everlife
5.1.7 KroniKare
5.1.8 Forefront Medical Technology
5.1.9 BetaLife
5.1.10 Raffles Medical Group
6.1 Regulatory and Reimbursement Landscape 39-44
6.1 Regulatory Landscape in Singapore
6.2 Reimbursement Scenario in Singapore
6.3 Reimbursement Process
Table of Content
CONTENT PG. NO.
5.1.4 Roche
5.1.5 Johnson & Johnson
5.1.6 Everlife
5.1.7 KroniKare
5.1.8 Forefront Medical Technology
5.1.9 BetaLife
5.1.10 Raffles Medical Group
6.1 Regulatory and Reimbursement Landscape 39-44
6.1 Regulatory Landscape in Singapore
6.2 Reimbursement Scenario in Singapore
6.3 Reimbursement Process
Table of Content
Singapore Diabetes Device Market Analysis
1. Market Overview
1. Market Overview
▪Diabetes devices are the tools or equipment diabetes patients use to regulate blood glucose
levels, prevent diabetes complications, lessen the burden of diabetes, and enhance the quality of
life. These devices assist in monitoring blood glucose levels, administering insulin, or both.
▪Diabetes devices provide real-time data and personalized recommendations, enabling individuals
to make informed decisions about their health
Key Features and advantages of various diabetes devices:
▪Insulin Pumps provides more precise insulin dosing, reduces the need for multiple daily injections, and can be
programmed to match individual needs
▪Continuous Glucose Monitors automatically estimate the blood glucose levels every few minutes throughout the
day and night
▪Smart Insulin Pens track insulin doses and timing, often connecting to smartphone apps, they help prevent
missed or double doses.
1.1 Diabetes Device Overview
levels, prevent diabetes complications, lessen the burden of diabetes, and enhance the quality of
life. These devices assist in monitoring blood glucose levels, administering insulin, or both.
▪Diabetes devices provide real-time data and personalized recommendations, enabling individuals
to make informed decisions about their health
Key Features and advantages of various diabetes devices:
▪Insulin Pumps provides more precise insulin dosing, reduces the need for multiple daily injections, and can be
programmed to match individual needs
▪Continuous Glucose Monitors automatically estimate the blood glucose levels every few minutes throughout the
day and night
▪Smart Insulin Pens track insulin doses and timing, often connecting to smartphone apps, they help prevent
missed or double doses.
1.1 Diabetes Device Overview
9 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
10.71
11.7
13.57
16
18.1
21.28
23.01
26.09
29.41
33.09
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Annual Revenue of Diabetes Device Market 2016-2025 ($Bn)
1.2 Diabetes Device Market Overview: Global (1/2)
643 Mn
Global prevalence of
diabetes projected to
2030
2.7 Bn
Adults estimated to be living
with obesity by 2025
6.7 Mn
Deaths globally due to
diabetes in 2021
537 Mn
Number of diabetics
worldwide in 2021
10.71
11.7
13.57
16
18.1
21.28
23.01
26.09
29.41
33.09
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Annual Revenue of Diabetes Device Market 2016-2025 ($Bn)
1.2 Diabetes Device Market Overview: Global (1/2)
643 Mn
Global prevalence of
diabetes projected to
2030
2.7 Bn
Adults estimated to be living
with obesity by 2025
6.7 Mn
Deaths globally due to
diabetes in 2021
537 Mn
Number of diabetics
worldwide in 2021
10 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Singapore Market
~$xx Bn Market Illustrative
1.2 Singapore Diabetes Device Market Overview: Global (2/2)
Singapore Market
~$xx Bn Market Illustrative
1.2 Singapore Diabetes Device Market Overview: Global (2/2)
11 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
12%
73%
15%
2013201420152016201720182019202020212022
Population of Singapore, (In Mn)
2013201420152016201720182019202020212022
GDP of Singapore, (In $Bn)
Population Split (2022)
0-14
15-64
65+
MaleFemale
By Age GroupBy Gender
▪Singapore is an aging country, as its median age is 42.8 years
which is higher than global median age
▪Country's population’s global share is 0.07% and it is increasing
at a rate of 0.65%
▪Life expectancy of female is 86.4 years and for male it is 82.1
years
▪Currently 100% of the population is urban in Singapore
▪Top 3 largest cities in Singapore are Bedok New Town, Ulu
Bedok, and Jurong Town
Illustrative
1.3 Economic Overview: Singapore
12%
73%
15%
2013201420152016201720182019202020212022
Population of Singapore, (In Mn)
2013201420152016201720182019202020212022
GDP of Singapore, (In $Bn)
Population Split (2022)
0-14
15-64
65+
MaleFemale
By Age GroupBy Gender
▪Singapore is an aging country, as its median age is 42.8 years
which is higher than global median age
▪Country's population’s global share is 0.07% and it is increasing
at a rate of 0.65%
▪Life expectancy of female is 86.4 years and for male it is 82.1
years
▪Currently 100% of the population is urban in Singapore
▪Top 3 largest cities in Singapore are Bedok New Town, Ulu
Bedok, and Jurong Town
Illustrative
1.3 Economic Overview: Singapore
12 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Illustrative
1.4 Singapore Diabetes Device Market Overview: Singapore
11.6%
Residents aged
between 18 to 74 years
are considered obese
24%
pregnant women in
Singapore are diagnosed
with gestational diabetes
14.9%
Adults have diabetes in
2021
8301
Deaths due to diabetes in
2021
2014 2015 2016 2017 2018 2019 2020 2021
Domestic General Government Health Expenditure (% of GDP) - Singapore
Illustrative
1.4 Singapore Diabetes Device Market Overview: Singapore
11.6%
Residents aged
between 18 to 74 years
are considered obese
24%
pregnant women in
Singapore are diagnosed
with gestational diabetes
14.9%
Adults have diabetes in
2021
8301
Deaths due to diabetes in
2021
2014 2015 2016 2017 2018 2019 2020 2021
Domestic General Government Health Expenditure (% of GDP) - Singapore
13 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
1.5 Healthcare Overview: Singapore
Public Healthcare
▪Universal Coverage: Singapore has a universal
healthcare system, with the government playing a key role
in financing and delivering healthcare services. It is
anchored by the Ministry of Health and comprises public
hospitals, specialty centers, polyclinics, and community
hospitals
▪Funding: The public healthcare system is funded through
a combination of government subsidies, mandatory
savings, and private insurance. Some of the key financing
schemes include MediSave, MediShield Life, MediFund
▪Specialized Care: Public hospitals and specialty centers
offer advanced tertiary care services, including specialized
treatments and procedures
▪Singapore's public healthcare system is known for its high
quality, efficiency, and positive health outcomes
Private Healthcare
▪Complimentary: The private healthcare sector in
Singapore complements the public system, offering
additional capacity and specialized services. It provides
additional capacity, specialized services, and more
personalized care options for those who can afford it
▪Services Offered: Private hospitals and clinics cater to
patients who can afford private insurance or are willing to
pay out-of-pocket. They offer a wide range of specialized
services including specialized cancer treatments,
advanced surgical procedures
▪Financing: Private healthcare is financed through a
combination of private insurance schemes and out-of-
pocket payments
1.5 Healthcare Overview: Singapore
Public Healthcare
▪Universal Coverage: Singapore has a universal
healthcare system, with the government playing a key role
in financing and delivering healthcare services. It is
anchored by the Ministry of Health and comprises public
hospitals, specialty centers, polyclinics, and community
hospitals
▪Funding: The public healthcare system is funded through
a combination of government subsidies, mandatory
savings, and private insurance. Some of the key financing
schemes include MediSave, MediShield Life, MediFund
▪Specialized Care: Public hospitals and specialty centers
offer advanced tertiary care services, including specialized
treatments and procedures
▪Singapore's public healthcare system is known for its high
quality, efficiency, and positive health outcomes
Private Healthcare
▪Complimentary: The private healthcare sector in
Singapore complements the public system, offering
additional capacity and specialized services. It provides
additional capacity, specialized services, and more
personalized care options for those who can afford it
▪Services Offered: Private hospitals and clinics cater to
patients who can afford private insurance or are willing to
pay out-of-pocket. They offer a wide range of specialized
services including specialized cancer treatments,
advanced surgical procedures
▪Financing: Private healthcare is financed through a
combination of private insurance schemes and out-of-
pocket payments
14 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare
$769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
As % Of GDP 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
▪National Health Expenditures (NHE) grew 2.7% to $4.3 Tn in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪Medicare spending grew 8.4% to $900.8 Bn in 2021, or 21% of total NHE
▪Private health insurance spending grew 5.8% to $1,211.4 Bn in 2021, or 28% of total NHE
▪Out of pocket spending grew 10.4% to $433.2 Bn in 2021, or 10% of total NHE
▪Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 Bn, or 14% of total NHE
▪Hospital expenditures grew 4.4% to $1,323.9 Bn in 2021, slower than the 6.2% growth in 2020
▪Physician and clinical services expenditures grew 5.6% to $864.6 Bn in 2021, slower growth than the 6.6% in 2020
▪Prescription drug spending increased 7.8% to $378.0 Bn in 2021, faster than the 3.7% growth in 2020
▪Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending
accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative
1.6 Budget of Singapore Government for Public Insurance
Proposed Budget By Category
Outlays 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2022-31
In Billions Of Dollars
Medicare
$769 $709 $766 $841 $840 $947 $1,014 $1,085 $1,227 $1,178 $1,325 $1,412 $10,633
As % Of GDP 3.7% 3.2% 3.3% 3.4% 3.3% 3.6% 3.7% 3.8% 4.1% 3.8% 4.1% 4.2% 3.7%
▪National Health Expenditures (NHE) grew 2.7% to $4.3 Tn in 2021, or $12,914 per person, and accounted for 18.3% of Gross Domestic Product (GDP)
▪Medicare spending grew 8.4% to $900.8 Bn in 2021, or 21% of total NHE
▪Private health insurance spending grew 5.8% to $1,211.4 Bn in 2021, or 28% of total NHE
▪Out of pocket spending grew 10.4% to $433.2 Bn in 2021, or 10% of total NHE
▪Other Third Party Payers and Programs and Public Health Activity spending declined 20.7% in 2021 to $596.6 Bn, or 14% of total NHE
▪Hospital expenditures grew 4.4% to $1,323.9 Bn in 2021, slower than the 6.2% growth in 2020
▪Physician and clinical services expenditures grew 5.6% to $864.6 Bn in 2021, slower growth than the 6.6% in 2020
▪Prescription drug spending increased 7.8% to $378.0 Bn in 2021, faster than the 3.7% growth in 2020
▪Largest shares of total health spending were sponsored by the federal government (34%) and the households (27%). The private business share of health spending
accounted for 17% of total health care spending, state and local governments accounted for 15%, and other private revenues accounted for 7%
Illustrative
1.6 Budget of Singapore Government for Public Insurance
15 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Company Name Type Year Key Pointers
Expansion
October,
2022
▪Dexcom, a global leader in continuous glucose monitoring (CGM)
systems, expanded its presence in Singapore
▪Dexcom's CGM devices are increasingly being adopted in Singapore to
help people with diabetes better manage their condition
Acquisition July, 2022
▪Everlife, a Singapore-based medical device distributor, acquired Forefront
Medical Technology, a contract manufacturer of disposable medical
devices
▪Forefront Medical Technology has expertise in diabetes devices like
insulin pens and pumps
Latest Deals in Singapore
Illustrative
1.7 Top Developments in Singapore
Company Name Type Year Key Pointers
Expansion
October,
2022
▪Dexcom, a global leader in continuous glucose monitoring (CGM)
systems, expanded its presence in Singapore
▪Dexcom's CGM devices are increasingly being adopted in Singapore to
help people with diabetes better manage their condition
Acquisition July, 2022
▪Everlife, a Singapore-based medical device distributor, acquired Forefront
Medical Technology, a contract manufacturer of disposable medical
devices
▪Forefront Medical Technology has expertise in diabetes devices like
insulin pens and pumps
Latest Deals in Singapore
Illustrative
1.7 Top Developments in Singapore
Singapore Diabetes Device Market Analysis
2. Epidemiology
2. Epidemiology
17 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Illustrative
2.1 Prevalence
▪Diabetes is a disorder that develops when the blood glucose levels rise over normal levels, owing to a defect in insulin production
that controls glucose levels
▪Blood glucose acts as the main source of energy and can be obtained from the food we consume. Insulin, the pancreatic hormone
maintains blood glucose levels. Defects in the synthesis of insulin in the body cannot regulate the blood glucose level and causes
diabetes
▪The Blood glucose level range in a normal individual is 70 – 100 mg/dL and in a diabetic patient it increases up to 80 – 130 mg/dL.
Diabetes care devices are used to monitor the glucose levels of a diabetic patient
▪According to the latest data from the International Diabetes Federation (IDF), the prevalence of diabetes among adults aged 20-79
years in Singapore was 11.6% in 2021, which translates to approximately 711,800 people living with the condition. This represents a
significant increase from the 2010 prevalence of 8.3% and the 2019 prevalence of 10.5%
▪IDF estimates that by 2045, the number of adults with diabetes in Singapore could reach 900,000, or 12.4% of the population
▪Type 2 diabetes accounts for over 90% of all diabetes cases in Singapore. The condition is closely linked to obesity and sedentary
lifestyles, characterized by prolonged sitting and lack of physical activity, are the major contributors to the high prevalence of type 2
diabetes in Singapore
Illustrative
2.1 Prevalence
▪Diabetes is a disorder that develops when the blood glucose levels rise over normal levels, owing to a defect in insulin production
that controls glucose levels
▪Blood glucose acts as the main source of energy and can be obtained from the food we consume. Insulin, the pancreatic hormone
maintains blood glucose levels. Defects in the synthesis of insulin in the body cannot regulate the blood glucose level and causes
diabetes
▪The Blood glucose level range in a normal individual is 70 – 100 mg/dL and in a diabetic patient it increases up to 80 – 130 mg/dL.
Diabetes care devices are used to monitor the glucose levels of a diabetic patient
▪According to the latest data from the International Diabetes Federation (IDF), the prevalence of diabetes among adults aged 20-79
years in Singapore was 11.6% in 2021, which translates to approximately 711,800 people living with the condition. This represents a
significant increase from the 2010 prevalence of 8.3% and the 2019 prevalence of 10.5%
▪IDF estimates that by 2045, the number of adults with diabetes in Singapore could reach 900,000, or 12.4% of the population
▪Type 2 diabetes accounts for over 90% of all diabetes cases in Singapore. The condition is closely linked to obesity and sedentary
lifestyles, characterized by prolonged sitting and lack of physical activity, are the major contributors to the high prevalence of type 2
diabetes in Singapore
18 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Illustrative
2.2 Diabetes Management Devices
Continuous Glucose Monitor
A continuous glucose monitor (CGM) is a medical device that tracks and monitors the blood glucose of a diabetic patient
throughout the day. This wearable technology is particularly useful for people with diabetes as it can help them manage glucose
levels
Insulin Pump
These are computerized devices that deliver insulin continuously under the skin. They can be programmed to deliver basal
insulin (background level) and bolus insulin (for meals). Insulin pumps offer more precise control over insulin delivery compared
to injections
Smart Insulin Pens
These are reusable pens that combine traditional insulin delivery with smartphone connectivity. Smart insulin pens can improve
medication adherence and simplify diabetes management
Blood Ketone Meters
These devices measure ketone levels in the blood. Monitoring ketone levels can help prevent diabetic ketoacidosis, a serious
complication of diabetes.
Illustrative
2.2 Diabetes Management Devices
Continuous Glucose Monitor
A continuous glucose monitor (CGM) is a medical device that tracks and monitors the blood glucose of a diabetic patient
throughout the day. This wearable technology is particularly useful for people with diabetes as it can help them manage glucose
levels
Insulin Pump
These are computerized devices that deliver insulin continuously under the skin. They can be programmed to deliver basal
insulin (background level) and bolus insulin (for meals). Insulin pumps offer more precise control over insulin delivery compared
to injections
Smart Insulin Pens
These are reusable pens that combine traditional insulin delivery with smartphone connectivity. Smart insulin pens can improve
medication adherence and simplify diabetes management
Blood Ketone Meters
These devices measure ketone levels in the blood. Monitoring ketone levels can help prevent diabetic ketoacidosis, a serious
complication of diabetes.
Singapore Diabetes Device Market Analysis
3. Market Size and Forecasting
3. Market Size and Forecasting
20 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
2023 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Singapore Diabetes Device Market Forecast, 2023-2030
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient ($Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Singapore Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Singapore Market Size ($Bn) 61 74 84 87 91 95 99 106
Illustrative
3.1 Singapore Diabetes Device Market Size and Forecasts
2023 2024F 2025F 2026F 2027F 2028F 2029F 2030F
Singapore Diabetes Device Market Forecast, 2023-2030
2023 2024 2025 2026 2027 2028 2029 2030
Major Markets Patient ($Mn) 2.74 2.82 2.90 2.94 2.98 3.02 3.07 3.12
Singapore Patient Size ($Bn) 0.51 0.61 0.68 0.69 0.70 0.71 0.72 0.73
% of Patients 18.75% 21.70% 23.56% 23.45% 23.42% 23.39% 23.34% 23.45%
Global Market Size ($Bn) 3,620 3,780 3,950 4,128 4,314 4,508 4,711 4,937
Singapore Market Size ($Bn) 61 74 84 87 91 95 99 106
Illustrative
3.1 Singapore Diabetes Device Market Size and Forecasts
21 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪In this section you will get an understanding of the segmentations which will cover the Singapore Diabetes Device Market
▪In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Device Type
Monitoring Devices
Management Devices
Distribution
Hospital Pharmacies
Retail Pharmacies
Diabetes Clinics/ Centers
Online Pharmacies
End User
Hospitals
Diagnostic Centers
Homecare
Illustrative
3.2 Snapshot of Singapore Diabetes Device Market Segmentation
▪In this section you will get an understanding of the segmentations which will cover the Singapore Diabetes Device Market
▪In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Device Type
Monitoring Devices
Management Devices
Distribution
Hospital Pharmacies
Retail Pharmacies
Diabetes Clinics/ Centers
Online Pharmacies
End User
Hospitals
Diagnostic Centers
Homecare
Illustrative
3.2 Snapshot of Singapore Diabetes Device Market Segmentation
22 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Singapore Diabetes Device Market Share, By Device Type
(2023)
Monitoring
Devices
Management
Devices
Illustrative
3.2.1 Market Segmentation: By Device Type
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Singapore Diabetes Device Market Share, By Device Type
(2023)
Monitoring
Devices
Management
Devices
Illustrative
3.2.1 Market Segmentation: By Device Type
23 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Singapore Diabetes Device Market Share, By Distribution
(2023)
Hospital
Pharmacies
Retail
Pharmacies
Diabetes
Clinics/
Centers
Online
Pharmacies
Illustrative
3.2.2 Market Segmentation: By Distribution
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Singapore Diabetes Device Market Share, By Distribution
(2023)
Hospital
Pharmacies
Retail
Pharmacies
Diabetes
Clinics/
Centers
Online
Pharmacies
Illustrative
3.2.2 Market Segmentation: By Distribution
24 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Singapore Diabetes Device Market Share, By End User
(2023)
Hospitals
Diagnostic
Centers
Homecare
Illustrative
3.2.3 Market Segmentation: By End User
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
Singapore Diabetes Device Market Share, By End User
(2023)
Hospitals
Diagnostic
Centers
Homecare
Illustrative
3.2.3 Market Segmentation: By End User
Singapore Diabetes Device Market Analysis
4. Market Dynamics
4. Market Dynamics
26 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
4.1.1
Increase in the
prevalence of diabetes
leads to an increase in
demand for effective
management tools
4.1.2
Advanced diabetes
tech in medical
tourism boosts
Singapore's device
market
4.1.3
Government support
and initiatives to use
advanced diabetes
devices enhance the
growth
4.2.1
Diabetes
management is
expensive, which
limits access to
some patients
4.2.2
Alternative
treatments are
posing a growing
threat to
businesses
4.2.3
Strict regulations
deter companies
from entering the
diabetes device
market
Illustrative
4. Snapshot Of Market Growth Drivers And Restraints
4.1.1
Increase in the
prevalence of diabetes
leads to an increase in
demand for effective
management tools
4.1.2
Advanced diabetes
tech in medical
tourism boosts
Singapore's device
market
4.1.3
Government support
and initiatives to use
advanced diabetes
devices enhance the
growth
4.2.1
Diabetes
management is
expensive, which
limits access to
some patients
4.2.2
Alternative
treatments are
posing a growing
threat to
businesses
4.2.3
Strict regulations
deter companies
from entering the
diabetes device
market
Illustrative
4. Snapshot Of Market Growth Drivers And Restraints
27 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Illustrative
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
4.1 Market Growth Drivers
4.1.1 Increase in the prevalence of diabetes leads to an increase in demand for effective management tools
Prevalence of Diabetes (2023-2030)
2023 2025 2030
Illustrative
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
4.1 Market Growth Drivers
4.1.1 Increase in the prevalence of diabetes leads to an increase in demand for effective management tools
Prevalence of Diabetes (2023-2030)
2023 2025 2030
28 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
2023 2025 2030
Illustrative
4.1 Market Growth Drivers
4.1.2 Advanced diabetes tech in medical tourism boosts Singapore's device market
Market Share of Diabetes Devices (2023-2030)
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
2023 2025 2030
Illustrative
4.1 Market Growth Drivers
4.1.2 Advanced diabetes tech in medical tourism boosts Singapore's device market
Market Share of Diabetes Devices (2023-2030)
29 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
Illustrative
4.1 Market Growth Drivers
4.1.3 Government support and initiatives to use advanced diabetes devices enhance the growth of the
diabetes device market
Grants for Device Purchase
▪Please be aware that this sample report is intended to provide you with a
brief overview of the kind of information and analysis that will be
presented in the final report
▪In order to obtain access to all of the information that you are seeking,
you will need to purchase the final report
▪Final report will be comprehensive and detailed, and it will include data,
analysis, trends, and other relevant information related to the topic or
subject matter of interest
Illustrative
4.1 Market Growth Drivers
4.1.3 Government support and initiatives to use advanced diabetes devices enhance the growth of the
diabetes device market
Grants for Device Purchase
30 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
4.2.1 Diabetes management is
expensive, which limits access
to some patients
▪Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
4.2.2 Alternative treatments are
posing a growing threat to
businesses
▪Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
4.2.3 Strict regulations deter
companies from entering the
diabetes device market
▪Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
▪Final report will be
comprehensive and detailed, and
it will include data, analysis,
trends, and other relevant
information related to the topic or
subject matter of interest
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative
4.2 Market Growth Restraints
4.2.1 Diabetes management is
expensive, which limits access
to some patients
▪Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
4.2.2 Alternative treatments are
posing a growing threat to
businesses
▪Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
4.2.3 Strict regulations deter
companies from entering the
diabetes device market
▪Please be aware that this sample
report is intended to provide you
with a brief overview of the kind
of information and analysis that
will be presented in the final
report
▪In order to obtain access to all of
the information that you are
seeking, you will need to
purchase the final report
▪Final report will be
comprehensive and detailed, and
it will include data, analysis,
trends, and other relevant
information related to the topic or
subject matter of interest
Our analysis will thoroughly investigate the key restraints that may significantly impact business
operations and growth.
Illustrative
4.2 Market Growth Restraints
Singapore Diabetes Device Market Analysis
5. Competitive Landscape
5. Competitive Landscape
32 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪Here is the list of top 10 companies which
will cover in the final report
▪Each company will have slides for
oOverview
oKey details
oOfferings
oName of products
oRecent activities/ Press Coverage
oDistribution and Vendor Partners
oMergers, Acquisitions and
Collaboration
oFinancials
▪If there are specific companies that you
would like to be included in the report,
please let us know via email
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
Medtronic1 Everlife6
Dexcom2 KroniKare 7
Abbott Laboratories3
Forefront Medical
Technology
8
Roche4 BetaLife 9
Johnson & Johnson5
Raffles Medical
Group
10
Illustrative
Global Player Local Player
5.1 Key Players in Singapore Diabetes Device Market
▪Here is the list of top 10 companies which
will cover in the final report
▪Each company will have slides for
oOverview
oKey details
oOfferings
oName of products
oRecent activities/ Press Coverage
oDistribution and Vendor Partners
oMergers, Acquisitions and
Collaboration
oFinancials
▪If there are specific companies that you
would like to be included in the report,
please let us know via email
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
Medtronic1 Everlife6
Dexcom2 KroniKare 7
Abbott Laboratories3
Forefront Medical
Technology
8
Roche4 BetaLife 9
Johnson & Johnson5
Raffles Medical
Group
10
Illustrative
Global Player Local Player
5.1 Key Players in Singapore Diabetes Device Market
33 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Founded In: 1949
HQ: Fridley, Minnesota, US
Type: Public
Revenue: $31.7 Bn (Global)
Website: www.medtronic.com
▪Medtronic offers a wide range of medical devices and therapies
across various therapeutic areas, including diabetes management,
cardiac care, neuroscience, and surgical technologies.
▪It has a significant international presence, with operations in over
150 countries and close to 10,000 employees in the Asia Pacific
region alone, including a regional headquarters in Singapore
▪Medtronic invests heavily in research and development to drive
innovation
Offerings
➢Medical Device and Therapies
➢Neurostimulation Devices
➢Surgical Instruments
➢Insulin Pumps and CGM
systems
Recent Activity / Press Coverage
▪June 21, 2024 — New MiniMed 780G system data demonstrates the ability to address persistent blood sugar challenges for people with type 1
diabetes
▪MiniMed 780G is the only automated insulin delivery system in the world with Meal Detection technology* that automatically adjusts insulin and
corrects† glucose levels every 5 minutes
▪April 26, 2024 — Medtronic receives FDA approval for Inceptiv closed-loop spinal cord stimulator
▪Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts
stimulation in real time, keeping therapy in harmony with the motions of daily life
▪January 08, 2024 — FDA approves Medtronic Percept RC neurostimulator with exclusive BrainSense technology
▪The Percept family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement
disorders such as Parkinson's disease, essential tremor, and dystonia* as well as epilepsy
5.1.1 Medtronic (Continued)
Founded In: 1949
HQ: Fridley, Minnesota, US
Type: Public
Revenue: $31.7 Bn (Global)
Website: www.medtronic.com
▪Medtronic offers a wide range of medical devices and therapies
across various therapeutic areas, including diabetes management,
cardiac care, neuroscience, and surgical technologies.
▪It has a significant international presence, with operations in over
150 countries and close to 10,000 employees in the Asia Pacific
region alone, including a regional headquarters in Singapore
▪Medtronic invests heavily in research and development to drive
innovation
Offerings
➢Medical Device and Therapies
➢Neurostimulation Devices
➢Surgical Instruments
➢Insulin Pumps and CGM
systems
Recent Activity / Press Coverage
▪June 21, 2024 — New MiniMed 780G system data demonstrates the ability to address persistent blood sugar challenges for people with type 1
diabetes
▪MiniMed 780G is the only automated insulin delivery system in the world with Meal Detection technology* that automatically adjusts insulin and
corrects† glucose levels every 5 minutes
▪April 26, 2024 — Medtronic receives FDA approval for Inceptiv closed-loop spinal cord stimulator
▪Inceptiv is the first Medtronic SCS device to offer a closed-loop feature that senses biological signals along the spinal cord and automatically adjusts
stimulation in real time, keeping therapy in harmony with the motions of daily life
▪January 08, 2024 — FDA approves Medtronic Percept RC neurostimulator with exclusive BrainSense technology
▪The Percept family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement
disorders such as Parkinson's disease, essential tremor, and dystonia* as well as epilepsy
5.1.1 Medtronic (Continued)
34 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Company Name Type Year Key Pointers
Partnership June, 2024
▪Medtronic announced partnership with Merit Medical Systems to offer the
Kyphon KyphoFlex unipedicular balloon catheter for treating vertebral
compression fractures in United States
▪Kyphon KyphoFlex is designed to achieve controlled, precise, targeted
cavity creation in vertebral augmentation procedures. The unipedicular
solution will be complementary to Medtronic’s current bipedicular balloon
kyphoplasty solution
Latest Deals in Medtronic
Illustrative
5.1.1 Medtronic (Continued)
Company Name Type Year Key Pointers
Partnership June, 2024
▪Medtronic announced partnership with Merit Medical Systems to offer the
Kyphon KyphoFlex unipedicular balloon catheter for treating vertebral
compression fractures in United States
▪Kyphon KyphoFlex is designed to achieve controlled, precise, targeted
cavity creation in vertebral augmentation procedures. The unipedicular
solution will be complementary to Medtronic’s current bipedicular balloon
kyphoplasty solution
Latest Deals in Medtronic
Illustrative
5.1.1 Medtronic (Continued)
35 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
2020202120222023F2024F2025F2026F2027F2028F2029F2030F
Revenues ($Bn), 2020-2030
Breakdown of Net Revenue by Segment, 2023
1 2 3 4
Illustrative
5.1.1 Medtronic (Continued)
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
2020202120222023F2024F2025F2026F2027F2028F2029F2030F
Revenues ($Bn), 2020-2030
Breakdown of Net Revenue by Segment, 2023
1 2 3 4
Illustrative
5.1.1 Medtronic (Continued)
36 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Founded In:
HQ:
Type:
Revenue:
Website:
Offerings
Recent Activity / Press Coverage
5.1.2 Company 2
Illustrative
Founded In:
HQ:
Type:
Revenue:
Website:
Offerings
Recent Activity / Press Coverage
5.1.2 Company 2
Illustrative
37 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Company Name Type Year Key Pointers
Latest Deals in CompanyName
Illustrative
5.1.2 Company 2 (Continued)
Company Name Type Year Key Pointers
Latest Deals in CompanyName
Illustrative
5.1.2 Company 2 (Continued)
38 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
2020202120222023F2024F2025F2026F2027F2028F2029F2030F
Revenues ($Bn), 2020-2030
Breakdown of Net Revenue by Segment, 2023
1 2 3 4
Illustrative
5.1.2 Company 2 (Continued)
▪Please be aware that this sample report is
intended to provide you with a brief
overview of the kind of information and
analysis that will be presented in the final
report
▪In order to obtain access to all of the
information that you are seeking, you will
need to purchase the final report
▪Final report will be comprehensive and
detailed, and it will include data, analysis,
trends, and other relevant information
related to the topic or subject matter of
interest
2020202120222023F2024F2025F2026F2027F2028F2029F2030F
Revenues ($Bn), 2020-2030
Breakdown of Net Revenue by Segment, 2023
1 2 3 4
Illustrative
5.1.2 Company 2 (Continued)
Singapore Diabetes Device Market Analysis
6. Regulatory and Reimbursement Landscape
6. Regulatory and Reimbursement Landscape
40 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
The Ministry of Health (MOH) is the primary governmental body responsible for the health of the people and the overall healthcare system in
Singapore. Its key governmental agencies responsible for the administration of drugs and medical devices are as follows:
Regulatory For Medical Devices In Singapore
6.1 Regulatory Landscape in Singapore
Health Sciences Authority (HSA), is the regulatory agency overseeing medical devices in Singapore. It oversees the export,
import, and distribution of medical devices in the country
The HSA classifies medical devices into various classes (A, B, C, D) based on risk factors. Almost every medical device is
subject to regulatory oversight, except for Class A products considered low-risk
The registration process for Class B, C, and D devices involves submitting detailed technical documentation, clinical evidence,
and quality management system information to the HSA. This ensures the devices meet safety, performance, and quality
standards. The HSA review can take 4-12 months depending on the device class and complexity. Approved devices are then
listed on the Singapore Medical Device Register, which allows them to be legally marketed in the country
Singapore is part of the ASEAN Medical Device Directive, which aims to establish a harmonized system for registering and
evaluating medical devices across Southeast Asia. This can help streamline the approval process for companies looking to
access the regional market
Illustrative
The Ministry of Health (MOH) is the primary governmental body responsible for the health of the people and the overall healthcare system in
Singapore. Its key governmental agencies responsible for the administration of drugs and medical devices are as follows:
Regulatory For Medical Devices In Singapore
6.1 Regulatory Landscape in Singapore
Health Sciences Authority (HSA), is the regulatory agency overseeing medical devices in Singapore. It oversees the export,
import, and distribution of medical devices in the country
The HSA classifies medical devices into various classes (A, B, C, D) based on risk factors. Almost every medical device is
subject to regulatory oversight, except for Class A products considered low-risk
The registration process for Class B, C, and D devices involves submitting detailed technical documentation, clinical evidence,
and quality management system information to the HSA. This ensures the devices meet safety, performance, and quality
standards. The HSA review can take 4-12 months depending on the device class and complexity. Approved devices are then
listed on the Singapore Medical Device Register, which allows them to be legally marketed in the country
Singapore is part of the ASEAN Medical Device Directive, which aims to establish a harmonized system for registering and
evaluating medical devices across Southeast Asia. This can help streamline the approval process for companies looking to
access the regional market
Illustrative
41 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Key Legislation
The Health Products Act is a key piece of legislation in Singapore that governs the regulation of health products, including medical devices. It
provides a comprehensive framework for regulating the manufacture, import, supply, presentation, and advertisement of health products
Authorization
All medical devices, except for low-risk Class A devices, must be registered and approved by the Health Sciences Authority (HSA) before they
can be supplied in Singapore. The registration process involves submitting technical documentation, clinical evidence, quality management
system information, and other required documents
Evaluation: The specific evaluation route depends on the device's risk class, prior approvals from reference regulatory agencies, and safety
marketing history
Approval: Once the HSA reviews the submitted documents and is satisfied with the device's safety and performance, it issues a condition of
approval. The approved devices are included in the Singapore Medical Device Register (SMDR)
Reimbursement
MediShield Life is the basic health insurance scheme covering all Singaporeans and permanent residents that provides partial coverage for
some medical devices. The Agency for Care Effectiveness (ACE) conducts health technology assessments (HTAs) to evaluate the clinical and
cost-effectiveness of new drugs and devices
Regulatory Framework For The Authorization, Pricing, And Reimbursement Of Drugs
6.2 Reimbursement Scenario in Singapore
Illustrative
Key Legislation
The Health Products Act is a key piece of legislation in Singapore that governs the regulation of health products, including medical devices. It
provides a comprehensive framework for regulating the manufacture, import, supply, presentation, and advertisement of health products
Authorization
All medical devices, except for low-risk Class A devices, must be registered and approved by the Health Sciences Authority (HSA) before they
can be supplied in Singapore. The registration process involves submitting technical documentation, clinical evidence, quality management
system information, and other required documents
Evaluation: The specific evaluation route depends on the device's risk class, prior approvals from reference regulatory agencies, and safety
marketing history
Approval: Once the HSA reviews the submitted documents and is satisfied with the device's safety and performance, it issues a condition of
approval. The approved devices are included in the Singapore Medical Device Register (SMDR)
Reimbursement
MediShield Life is the basic health insurance scheme covering all Singaporeans and permanent residents that provides partial coverage for
some medical devices. The Agency for Care Effectiveness (ACE) conducts health technology assessments (HTAs) to evaluate the clinical and
cost-effectiveness of new drugs and devices
Regulatory Framework For The Authorization, Pricing, And Reimbursement Of Drugs
6.2 Reimbursement Scenario in Singapore
Illustrative
42 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
Public healthcare coverage is provided by the government and includes
programs like Medicare and Medicaid
Medicare is a federal program that provides healthcare coverage to individuals
who are 65 years of age or older, as well as certain younger people with
disabilities
▪Shift towards value-based care has been a significant trend in Singapore healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care
38.9% 37.1% 35.6% 32.5% 31.5%
44.0%
46.0% 47.7%
51.0% 51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx
xx xx
xx xx
2019 2020 2021 2022 2023
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative
6.2 Reimbursement Scenario in Singapore (Continued)
Coverage Penetration (% Total Population) Source of Funding
Spend on Healthcare (%of Current Health Expenditure)
Reimbursement Market Trends
Public healthcare coverage is provided by the government and includes
programs like Medicare and Medicaid
Medicare is a federal program that provides healthcare coverage to individuals
who are 65 years of age or older, as well as certain younger people with
disabilities
▪Shift towards value-based care has been a significant trend in Singapore healthcare system, with payers and providers increasingly focused on improving patient
outcomes and reducing costs
▪This has led to the development of alternative payment models such as accountable care organizations (ACOs) and bundled payment arrangements, which
incentivize providers to deliver high-quality, cost-effective care
38.9% 37.1% 35.6% 32.5% 31.5%
44.0%
46.0% 47.7%
51.0% 51.8%
2017 2018 2019 2020 2021 2022 2023
Government Expenditure
Private Health Insurance
Out of Pocket
Other
NA NA
100% 100% 100% 100% 100%
xx
xx xx
xx xx
2019 2020 2021 2022 2023
Public Healthcare
Coverage
Private Coverage
6.3% 4.08% 5.1% 3.8% 2.2% 2.4% 3.6% GDP Growth (yoy)
14.7% 11.3% 15.5% 7.5% 4.2% NA NA HC Spend Growth (yoy)
Illustrative
6.2 Reimbursement Scenario in Singapore (Continued)
43 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
The reimbursement process in Singapore healthcare system can be complex and can vary depending on the type of healthcare
service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative
6.3 Reimbursement Process
The reimbursement process in Singapore healthcare system can be complex and can vary depending on the type of healthcare
service, the healthcare provider, and the insurance coverage. Here are the general steps involved in the reimbursement process:
▪Service or Treatment Provided: The healthcare provider performs a service or treatment for the patient
▪Billing: The healthcare provider submits a claim to the insurance company or other payer, requesting reimbursement for the
service provided
▪Adjudication: The insurance company or other payer reviews the claim to determine whether it meets the criteria for
reimbursement. This can involve verifying the patient's eligibility, reviewing the treatment provided, and checking for any potential
errors or fraud
▪Payment: If the claim is approved, the insurance company or other payer reimburses the healthcare provider for the service
provided, based on the negotiated payment rates or fee schedule
▪Patient Responsibility: Depending on the patient's insurance coverage, they may be responsible for paying a portion of the cost
of the service, such as deductibles, co-payments, or co-insurance
In order to obtain access to all of the information that you are seeking, you will need to purchase the final report
Final report will be comprehensive and detailed, and it will include data, analysis, trends, and other relevant information related to the
topic or subject matter of interest
Illustrative
6.3 Reimbursement Process
44 A Sample Report on Singapore Diabetes Device Market Analysis I Confidential
The reimbursement process in Singapore healthcare system can be
complex and can vary depending on the type of healthcare service, the
healthcare provider, and the insurance coverage. Here are the general
steps involved in the reimbursement process:
▪Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
MoH
Private Payers Public Payers
Health Technology Assessment
PaymentCoverageCoding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 32
Illustrative
6.3 Reimbursement Process (Continued)
The reimbursement process in Singapore healthcare system can be
complex and can vary depending on the type of healthcare service, the
healthcare provider, and the insurance coverage. Here are the general
steps involved in the reimbursement process:
▪Service or Treatment Provided: The healthcare provider performs a
service or treatment for the patient
▪Billing: The healthcare provider submits a claim to the insurance
company or other payer, requesting reimbursement for the service
provided
▪Adjudication: The insurance company or other payer reviews the claim
to determine whether it meets the criteria for reimbursement. This can
involve verifying the patient's eligibility, reviewing the treatment
provided, and checking for any potential errors or fraud
▪Payment: If the claim is approved, the insurance company or other
payer reimburses the healthcare provider for the service provided,
based on the negotiated payment rates or fee schedule
MoH
Private Payers Public Payers
Health Technology Assessment
PaymentCoverageCoding
Coding depends on availability code while coverage and
payment process decisions are made through an HTA.
Market Authorization
1 32
Illustrative
6.3 Reimbursement Process (Continued)
A division
of
of
Life-sciences Market Research
Reports you can trust
www. insig hts10. com
www.insights10.com
We maintain an extensive database comprising
over 30,000 syndicated market research reports
within the pharmaceuticals and healthcare sector,
offering a global, regional, and country-level
perspective. Our services also include the provision
of customized research reports, meticulously
tailored to align with your specific requirements.
Reports you can trust
www. insig hts10. com
www.insights10.com
We maintain an extensive database comprising
over 30,000 syndicated market research reports
within the pharmaceuticals and healthcare sector,
offering a global, regional, and country-level
perspective. Our services also include the provision
of customized research reports, meticulously
tailored to align with your specific requirements.
At Insights10, our extensive report
library spans a diverse range of
categories within the field of life
sciences.
Market Research
Reports across various
categories in healthcare
www. insig hts10. com
www.insights10.com
Digital
Health
Medical
Devices
Healthcare
Services
Rare
Diseases
Clinical
Trials
OTC &
Nutraceuticals
Pharma
(Diseases
& Drugs)
library spans a diverse range of
categories within the field of life
sciences.
Market Research
Reports across various
categories in healthcare
www. insig hts10. com
www.insights10.com
Digital
Health
Medical
Devices
Healthcare
Services
Rare
Diseases
Clinical
Trials
OTC &
Nutraceuticals
Pharma
(Diseases
& Drugs)
Click on the country to see the reports
available
Global Coverage
North America
•US
•Canada
Latin America
•Brazil
•Argentina
•Mexico
•Ecuador
•Venezuela
•Senegal
Europe
•UK
•Germany
•France
•Italy
•Spain
•Russia
•Netherlands
•Sweden
•Romania
•Switzerland
• Poland
• Austria
• Ireland
• Norway
• Denmark
• Belgium
• Portugal
• Ukraine
• Bulgaria
• Finland
APAC
• India
• China
• South Korea
• Japan
• Australia
• Indonesia
• Hong Kong
• New Zealand
• Philippines
• Singapore
• Malaysia
• Thailand
• Vietnam
Middle East
•UAE
•Saudi Arabia
•Turkey
•Lebanon
•Kuwait
•Qatar
Africa
•Egypt
•Kenya
•South Africa
•Algeria
•Nigeria
•Libya
•Tanzania
•Morocco
available
Global Coverage
North America
•US
•Canada
Latin America
•Brazil
•Argentina
•Mexico
•Ecuador
•Venezuela
•Senegal
Europe
•UK
•Germany
•France
•Italy
•Spain
•Russia
•Netherlands
•Sweden
•Romania
•Switzerland
• Poland
• Austria
• Ireland
• Norway
• Denmark
• Belgium
• Portugal
• Ukraine
• Bulgaria
• Finland
APAC
• India
• China
• South Korea
• Japan
• Australia
• Indonesia
• Hong Kong
• New Zealand
• Philippines
• Singapore
• Malaysia
• Thailand
• Vietnam
Middle East
•UAE
•Saudi Arabia
•Turkey
•Lebanon
•Kuwait
•Qatar
Africa
•Egypt
•Kenya
•South Africa
•Algeria
•Nigeria
•Libya
•Tanzania
•Morocco
What do our reports cover?
Market Overview
Growth Drivers & Growth Restraints
Epidemiology & Disease type
Market Size & Forecast
Competitive Landscape
Policy & Regulatory Landscape
Reimbursement Scenario
Recent Developments
Market Segmentation Factors Driving Future Growth
1
2
3
4
5
6
7
8
9
10
Market Overview
Growth Drivers & Growth Restraints
Epidemiology & Disease type
Market Size & Forecast
Competitive Landscape
Policy & Regulatory Landscape
Reimbursement Scenario
Recent Developments
Market Segmentation Factors Driving Future Growth
1
2
3
4
5
6
7
8
9
10
01 0302 04 05
Define
precise
research
questions
Validate data
through primary
research
interviews
Gather data
through
secondary
research
Forecast
market size
and segment
analysis
Extract key
insights from
the research
findings
06
Compile &
present a
comprehensive
analytical report
Our Research Process
Define
precise
research
questions
Validate data
through primary
research
interviews
Gather data
through
secondary
research
Forecast
market size
and segment
analysis
Extract key
insights from
the research
findings
06
Compile &
present a
comprehensive
analytical report
Our Research Process
Bottom Up Approach
Analyze product or treatment pricing
and reimbursement strategies
Evaluate consumer or patient
demographics and numbers
Predict future market
growth or decline based
on key market trends &
dynamics
Find
final
market size
Top Down Approach
Examine the total healthcare expenditure in
the targeted disease or service domain.
Assess the proportion of spending
allocated to the specific product or
treatment category.
Predict future market
growth or decline
based on key market
trends & dynamics
Find
final
market
size
Data Triangulation & Data Validation
Analyze product or treatment pricing
and reimbursement strategies
Evaluate consumer or patient
demographics and numbers
Predict future market
growth or decline based
on key market trends &
dynamics
Find
final
market size
Top Down Approach
Examine the total healthcare expenditure in
the targeted disease or service domain.
Assess the proportion of spending
allocated to the specific product or
treatment category.
Predict future market
growth or decline
based on key market
trends & dynamics
Find
final
market
size
Data Triangulation & Data Validation
2023
2024-
2030
Report Attribute
Quantitative Units
Pricing and Purchase
Revenue in USD Million/Billion (Mn/Bn)
Our pricing and purchase options are adaptable to
suit the specific scope of work.
Details Time Frame
Base
Year for
estimation
Forecast
Period
Report Scope
Delivery Timeline
Typically, the delivery of the final report falls within a
timeframe of 5 to 7 business days, but the exact
duration may vary depending on the project's scope.
Customization
We are pleased to offer you the option of
customizing the report to align with your specific
research requirements at no extra charge, provided
it falls within the defined scope of the project.
2024-
2030
Report Attribute
Quantitative Units
Pricing and Purchase
Revenue in USD Million/Billion (Mn/Bn)
Our pricing and purchase options are adaptable to
suit the specific scope of work.
Details Time Frame
Base
Year for
estimation
Forecast
Period
Report Scope
Delivery Timeline
Typically, the delivery of the final report falls within a
timeframe of 5 to 7 business days, but the exact
duration may vary depending on the project's scope.
Customization
We are pleased to offer you the option of
customizing the report to align with your specific
research requirements at no extra charge, provided
it falls within the defined scope of the project.
We have access to a multitude of highly
dependable data sources, supported by
years of experience that guide us in
discerning which sources are most reliable
and current for the specific information
needed.
Access to credible
data sources for
secondary research
www. insig hts10. com
www.insights10.com
Statistical
Databases
Annual
Reports
Trade
Publications
Online
Databases
Published
Research
Reports
White-
papers
Press
Releases
dependable data sources, supported by
years of experience that guide us in
discerning which sources are most reliable
and current for the specific information
needed.
Access to credible
data sources for
secondary research
www. insig hts10. com
www.insights10.com
Statistical
Databases
Annual
Reports
Trade
Publications
Online
Databases
Published
Research
Reports
White-
papers
Press
Releases
Reliable
Expert Verified
Realistic
Comprehensive
Easy to read
Our reports present data, which is
The report is prepared using a proven methodology and insightful
research
The report is prepared by a team of highly qualified & experienced
research analysts & vetted by our local associates
The report allows you to confidently make smarter business and
strategic decisions based on realistic findings
Covers everything you would need to know about the market
including market size, competitive analysis & much more
You do not have to be a market expert to understand what really is
happening on the market and how it works
Expert Verified
Realistic
Comprehensive
Easy to read
Our reports present data, which is
The report is prepared using a proven methodology and insightful
research
The report is prepared by a team of highly qualified & experienced
research analysts & vetted by our local associates
The report allows you to confidently make smarter business and
strategic decisions based on realistic findings
Covers everything you would need to know about the market
including market size, competitive analysis & much more
You do not have to be a market expert to understand what really is
happening on the market and how it works
Yearly Access
(Subscription)
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database Service
& KOL Mapping
Primary Research &
Interviews
Customized Market
Research Reports
Syndicated Market
Research Reports
Our Services
(Subscription)
Regulatory
Compliance
Competitive
Intelligence
Conference
Coverage
Full-Time
Engagement
Database Service
& KOL Mapping
Primary Research &
Interviews
Customized Market
Research Reports
Syndicated Market
Research Reports
Our Services
“The business decision-making process is no longer as
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market. We at
Insights10 are building the future of market research and
are committed to providing our clients with the right
intelligence and insights to make business decisions
quickly and efficiently.
Insights10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with
some of the best organizations in the world, generating
insights that provides substantial competitive advantage.”
Dr. Purav Gandhi, Founder & CEO
Click to watch Our Introductory Video here
CEO Speaks
straightforward as it used to be. It requires insights
generated at the right time, based on reliable data
interpreted in a nuanced manner for each market. We at
Insights10 are building the future of market research and
are committed to providing our clients with the right
intelligence and insights to make business decisions
quickly and efficiently.
Insights10 is a unique platform that combines deep
domain expertise, nuanced data at a country and
functional area level, and years of experience working with
some of the best organizations in the world, generating
insights that provides substantial competitive advantage.”
Dr. Purav Gandhi, Founder & CEO
Click to watch Our Introductory Video here
CEO Speaks
Purav is a physician and an
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager
Leadership Team
entrepreneur with 12+ years of
experience in Healthcare & Life
Sciences industry spanning across
strategy, market access, health
informatics and RWE, digital health,
analytics and data science. Purav
studied medicine from Gujarat
University and also completed his MBA
from IIM-Kozhikode. Purav started his
career with Deloitte working on strategy
consulting engagements and also co-
founded ConvergeHealth by Deloitte.
Anish has 15+ years of
experience in management
consulting in the Life Sciences
sector, and has worked with
diverse multinational firms in
the US, India, Middle East and
APAC regions. His primary area
of interest is Customer and
Market Strategy, Market
Access, and Digital Health with
special focus on emerging
markets like Africa, Middle East
and APAC.
Dr. Purav Gandhi
Founder & CEO
Anish Swaminathan
Director
Mukesh is an engineering graduate with
an MBA in Marketing. He is a seasoned
healthcare market research &
marketing professional with a
progressive experience of over 20
years in Life Sciences, Healthcare
services, Pharma and Medical Device
sectors. With an in-depth understanding
of primary research, he has conducted
hundreds of interviews of various
stakeholders in pharma & healthcare &
completed several research projects
across life sciences industry.
Ritu has over 6 years of experience in
strategy building, market assessments,
market sizing, and RWE for global MNC
healthcare & biopharma clients across
diff. markets (America, Europe, Africa,
APAC and Middle East). Her areas of
expertise include: Indentifying emerging
trends in life sciences industry,
Competitor landscape assessment,
Disease opportunity assessments etc.
She is a pro in secondary and primary
research with a deep domain expertise
in healthcare sector.
Mukesh Nayak
Head – Marketing & Research
Ritu Baliya
Engagement Manager
Leadership Team
@Our Team
@Work
Beyond Work
… and many more
Pi-SM
GmbH
Our Clients
Pi-SM
GmbH
Our Clients
I've had the pleasure of availing Insights10’s services several times, and I've always
been impressed by their expertise, professionalism, and dedication to providing us with
the highest quality data and insights. Whether one is looking to launch a new product,
expand into a new market, or better understand one's target customers, Insights10
insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and they use
their knowledge to develop customized research solutions that meet the specific needs
of each client. I highly recommend Insights10 to anyone looking for a reliable and
experienced partner in healthcare market research. They're a valuable asset to any
company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)
What our clients say
been impressed by their expertise, professionalism, and dedication to providing us with
the highest quality data and insights. Whether one is looking to launch a new product,
expand into a new market, or better understand one's target customers, Insights10
insures achieving the goals.
Their team of experts has a deep understanding of the healthcare industry, and they use
their knowledge to develop customized research solutions that meet the specific needs
of each client. I highly recommend Insights10 to anyone looking for a reliable and
experienced partner in healthcare market research. They're a valuable asset to any
company that wants to succeed in this dynamic sector.
Sid Panigrahy
Founder-CEO, MediGlobo Inc.,
(Healthcare - Group Company of Omi Holdings, Inc) Tampa, Florida (USA)
What our clients say
Dear Insights10 Team, I wanted to thank you all for the great work you conducted
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis. The
quality of the report was excellent, and you managed to complete it in record time. I was
also impressed by your quick turnaround on the topics discussed as a follow up after the
report's first version; you managed to gather the information required, plus a very good
analysis.
I will definitely consider working with you again if the opportunity arises, and will not
hesitate in recommending you to colleagues working in the field Thank you again for
your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID
What our clients say
producing the Kenya Medical and Diagnostic Laboratory Service Market Analysis. The
quality of the report was excellent, and you managed to complete it in record time. I was
also impressed by your quick turnaround on the topics discussed as a follow up after the
report's first version; you managed to gather the information required, plus a very good
analysis.
I will definitely consider working with you again if the opportunity arises, and will not
hesitate in recommending you to colleagues working in the field Thank you again for
your professionalism and team work. It was a pleasure working with you.
Lelio Marmora
CEO, The Management Lab, Geneva
Ex. Executive Director, UNITAID
What our clients say
Michael Blumberg Youssef Mallat
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health,London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, France, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.
What our clients say
Wissem Menad
Dr. Robert Ryan
Co Founder GFAU Pty Ltd., Australia
Co Founder – Embi, Optimum Oral care, Australia
Opusline, A part of Accenture, Paris
Senior Manager Segment Marketing
Performance Health,London, UK
Chief Executive Officer, Innova Therapeutics, Inc., USA
We engaged INSIGHTS10 to assist us with our research requirements
for the Oral Care Market sector in Australia. We been very impressed
with the depth and quality of data and equally with the personal
service we experience from the management team on our account.
They understand our business, our challenges and our goals. There is
a real sense of partnership as we continue to work together.
The info you delivered on the European Patient
Support Market with a deep dive into countries
like Spain, Germany, Italy, France, UK and
Belgium, was very useful.
Insights10 has been a great resource for
getting a detailed report on the UK
Physiotherapy Market. Usually I had multiple
sources for getting global reports, but now I
can get in-depth country reports from
Insights10 which has been a game changer.
We were looking for very specific information regarding Abu Dhabi
Oncology Drugs Market. The insights provided by Insights10 is
fantastic and they just took less than three days to deliver the report.
What our clients say
Thank You
www. insig hts10. com
www.insights10.com
Email: [email protected]
India: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?
www. insig hts10. com
www.insights10.com
Email: [email protected]
India: (+91) 931 639 7935
We would be happy to help.
Do you have
any questions?
Categories
GeneralDownload
Download Slideshow Get the original presentation fileQuick Actions
Statistics
- Views 78
- Slides 65
- Age 476 days
Related Slideshows
22
Pray For The Peace Of Jerusalem and You Will Prosper
RodolfoMoralesMarcuc
45 views
26
Don_t_Waste_Your_Life_God.....powerpoint
chalobrido8
48 views
31
VILLASUR_FACTORS_TO_CONSIDER_IN_PLATING_SALAD_10-13.pdf
JaiJai148317
44 views
14
Fertility awareness methods for women in the society
Isaiah47
41 views
35
Chapter 5 Arithmetic Functions Computer Organisation and Architecture
RitikSharma297999
43 views
5
syakira bhasa inggris (1) (1).pptx.......
ourcommunity56
42 views